Randomized phase III trial comparing induction chemotherapy followed by radiotherapy to concomitant chemoradiotherapy for laryngeal preservation in T3M0 pyriform sinus carcinoma

Acta Oto-Laryngologica

Volumn 130, Issue 1, 2010, Pages 150-155

  Prades, Jean Michel ^a   Lallemant, Benjamin ^d   Garrel, Renaud ^e   Reyt, Emile ^f   Righini, Christian ^f   Schmitt, Thierry ^b   Remini, Nagib ^b   Saban Roche, Lea ^b   Timoshenko, Andrei P ^a   Trombert, Beatrice ^c   Guerrier, Bernard ^e  

^a UNIVERSITÉ JEAN MONNET   (France)

^b North Hospital   (France)

^c UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^d NÎMES UNIVERSITY HOSPITAL   (France)

^e GUI DE CHAULIAC HOSPITAL   (France)

^f UNIV GRENOBLE ALPES   (France)

Author keywords

Head and neck cancer; Hypopharynx; Organ preservation strategy

Indexed keywords

CISPLATIN; FLUOROURACIL; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISTANT METASTASIS; DRUG FATALITY; ENDOSCOPY; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYPOPHARYNX CARCINOMA; INTERMETHOD COMPARISON; LARYNX; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUTROPENIA; ORGAN PRESERVATION; PHASE 3 CLINICAL TRIAL; PIRIFORM RECESS CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT RESPONSE; ADJUVANT THERAPY; CANCER STAGING; CARCINOMA, SQUAMOUS CELL; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; HYPOPHARYNGEAL NEOPLASMS; LARYNGECTOMY; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROGNOSIS; PROSPECTIVE STUDY; PYRIFORM SINUS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CAUSE OF DEATH; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; HYPOPHARYNGEAL NEOPLASMS; LARYNGECTOMY; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; PROSPECTIVE STUDIES; PYRIFORM SINUS;

EID: 75449120095     PISSN: 00016489     EISSN: 16512553     Source Type: Journal    
DOI: 10.3109/00016480902914080     Document Type: Article

References (20)

1. Ferlay J, Bray F, Pisani P, Parkin DM. Cancer incidence, mortality and prevalence worldwide. Version 1.0. International Agency for Research on Cancer (IARC) Cancer Base no. 5. Lyon, France: IARC Press, 2001.
2. Hussey DH, Latourette HB, Panje WR. Head and neck cancer: an analysis of the incidence, patterns of treatment and survival at the University of Iowa. Ann Otol Rhinol Laryngol Suppl 1991;/100(Suppl 152):/2-16.
3. Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Metaanalysis of Chemotherapy on Head and Neck Cancer. Lancet 2000;/355:/949-55.
4. Pignon JP, Hill C. Meta-analysis of randomized clinical trials in oncology. Lancet Oncol 2001;/2:/475-82.
5. Lefebvre JL, Chevalier D, Luboinski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. EORTC Head and Neck Cancer Cooperative Group. J Natl Cancer Inst 1996;/88:/890-9.
6. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;/349:/2091-8.
7. Hinerman RW, Amdur RJ, Mendenhall WM, Villaret DB, Robbins KT. Hypopharyngeal carcinoma. Curr Treat Options Oncol 2002;/3:/41-9.
8. Prades JM, Timoshenko AP, Schmitt TH, Delolme MP, Francoz M, Martin C, et al. Planned neck dissection before combined chemoradiation for pyriform sinus carcinoma. Acta Otolaryngol 2008;/128:/324-8.
9. Wolf GT. Commentary: phase III trial to preserve the larynx: induction chemotherapy and radiotherapy versus concurrent chemotherapy and radiotherapy versus radiotherapyintergroup trial R91-11. J Clin Oncol 2001;/19(18 Suppl):/ 285S-31S.
10. Prades JM, Schmitt TM, Timoshenko AP, Simon PG, de Cornulier J, Durand M, et al. Concomitant chemoradiotherapy in pyriform sinus carcinoma. Arch Otolaryngol Head Neck Surg 2002;/128:/384-8.
11. Bensadoun RJ, Bénézery K, Dassonville O, Magné N, Poissonnet G, Ramaiöli A, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2 years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys 2006;/ 64:/983-94.
12. Staar S, Rudat V, Stuetzer H, Dietz A, Volling P, Schroeder M, et al. Intensified hyperfractionated accelerated radiotherapy limits the additional benefit of simultaneous chemotherapy- results of a multicentric randomized German trial in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 2001;/50:/1161-71.
13. Yoon MS, Chung WK, Ahn SJ, Nam TK, Nah BS, Song JY, et al. Concurrent chemoradiotherapy with cisplatin and fluorouracil for locally advanced hypopharyngeal carcinoma. Acta Otolaryngol 2008;/128:/590-6.
14. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007;/ 357:/1695-704.
15. Haddad R, Tishler R, Wirth L, Norris CM, Goguen L, Sullivan C, et al. Rate of pathologic complete responses to docetaxel, cisplatin and fluorouracil induction chemotherapy in patients with squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2006;/132:/678-81.
16. Hitt R, López-Pousa A, Martínez-Trufero J, Escrig V, Carles J, Rizo A, et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J Clin Oncol 2005;/ 23:/8636-45.
17. Calais G, Pointreau Y, Alfonsi M, Sire C, Tuchais C, Tortochaux J, et al. Randomized phase III trial comparing induction chemotherapy using cisplatin (P), fluorouracil (F) with or without docetaxel (T) for organ preservation in hypopharynx and larynx cancer. Preliminary results of GORTEC 2000-2001. J Clin Oncol 2006;/24:/5506 (abstract).
18. Hitt R, Grau J, Lopez-Pousa A, Berrocal A, Garcia-Giron C, Belon J, et al. Randomized phase II-III clinical trial of induction chemotherapy (IC) with either cisplatin-5-fluorouracil (PF) or docetaxel-cisplatin-5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. CRT alone for patients with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2006;24:5515 (abstract).
19. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous- cell carcinoma of the head and neck. N Engl J Med 2006;/354:/567-78.
20. Posner MR, Wirth LJ. Cetuximab and radiotherapy for head and neck cancer. N Engl J Med 2006;/354:/634-6.